Literature DB >> 19488873

A whole-genome amplification protocol for a wide variety of DNAs, including those from formalin-fixed and paraffin-embedded tissue.

Pamela L Paris1.   

Abstract

High-resolution genomic arrays and next-generation sequencers are some of the genome-based technologies poised to make significant contributions in the near future to basic and clinical science. The success of these technologies, and most certainly their translation into the clinic, will require that they produce high quality, reproducible data from small archived tumor specimens, including biopsies. DNA from patient samples, especially archival tissue, can be a limiting factor and lead to the need for amplification of the starting material. A variety of whole-genome amplification techniques are available, but choosing the most reliable, reproducible amplification technology that will be suitable for use across a wide spectrum of clinical specimens is essential. Sigma's whole-genome amplification kit provides a robust, highly reliable, and versatile amplification system across a variety of DNA sources. This chapter will detail Sigma's amplification protocol along with an optimized DNA extraction protocol for formalin-fixed and paraffin-embedded tissue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19488873     DOI: 10.1007/978-1-60327-192-9_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Evaluation of affinity-based genome-wide DNA methylation data: effects of CpG density, amplification bias, and copy number variation.

Authors:  Mark D Robinson; Clare Stirzaker; Aaron L Statham; Marcel W Coolen; Jenny Z Song; Shalima S Nair; Dario Strbenac; Terence P Speed; Susan J Clark
Journal:  Genome Res       Date:  2010-11-02       Impact factor: 9.043

2.  The non-crosslinking fixative RCL2®-CS100 is compatible with both pathology diagnosis and molecular analyses.

Authors:  Florence Boissière-Michot; Amélie Denouël; Nathalie Boulle; Carole Guillaume; Béatrice Orsetti; Evelyne Lopez-Crapez; Marie-Christine Chateau; Frédéric Bibeau
Journal:  Pathol Oncol Res       Date:  2012-08-15       Impact factor: 3.201

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.